☆ 4.5 Editorial Material

The Lungs in Heart Failure Not an Innocent Bystander

JACC-HEART FAILURE (2016)

期刊

JACC-HEART FAILURE

卷 4, 期 6, 页码 450-452

出版社

ELSEVIER SCI LTD

DOI: 10.1016/j.jchf.2016.04.005

关键词

diffusion capacity; heart failure; hypertension; pulmonary; smoking; survival

类别

Cardiac & Cardiovascular Systems

资金

NHLBI NIH HHS [R01 HL128526, R01 HL126638] Funding Source: Medline

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Medicine, General & Internal

Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension

Eleni Diamanti, Vasiliki Karava, Patrick Yerly, John David Aubert

Summary: This study investigated the association between DLCO and PH severity and survival, finding that DLCO is negatively associated with transplant-free survival in PH patients. The inclusion of DLCO into a PH risk stratification score shows promise and requires further investigation.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Review Respiratory System

New trends in pulmonary hypertension

Sarah Cullivan, Sean Gaine, Olivier Sitbon

Summary: Pulmonary hypertension is a prevalent disease with high morbidity and mortality. Efforts have been made to improve disease recognition, diagnosis, and management, reflected in the updated guidelines. Changes in the definition, risk stratification, and emphasis on comorbidities and phenotyping provide new opportunities for early identification and patient-centered treatment decisions. New treatment pathways and potential targeted therapies are emerging, along with the recognition of the importance of supervised training and interventional therapies. This article highlights the trends in pulmonary hypertension, focusing on the revised guidelines.

EUROPEAN RESPIRATORY REVIEW (2023)

添加到收藏夹

Review Respiratory System

Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review

Katarina Zeder, Chiara Banfi, Gregor Steinrisser-Allex, Bradley A. Maron, Marc Humbert, Gregory D. Lewis, Andrea Berghold, Horst Olschewski, Gabor Kovacs

Summary: This study aimed to identify parameters related to abnormal haemodynamic response during exercise, and provide optimal prognostic and differential-diagnostic value. The findings indicated that mPAP/CO slope, PAWP/CO slope, and peak cardiac index (or CO) were the most consistent prognostic haemodynamic parameters. The study also established cut-off values for survival and cardiovascular events. Age was found to have a significant impact on the upper limits of normal for mPAP/CO slope and PAWP/CO slope.

EUROPEAN RESPIRATORY JOURNAL (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Osteopontin in Pulmonary Hypertension

Argen Mamazhakypov, Abdirashit Maripov, Akpay S. Sarybaev, Ralph Theo Schermuly, Akylbek Sydykov

Summary: Pulmonary hypertension (PH) is characterized by elevated pulmonary arterial pressure and vascular remodeling. Circulating osteopontin has been suggested as a biomarker of PH progression and right ventricular dysfunction. Preclinical studies have shown that osteopontin plays a role in PH pathogenesis by modulating various cellular processes. This article provides an overview of osteopontin regulation and its impact on pulmonary vascular remodeling, as well as the potential of targeting osteopontin for PH management.

BIOMEDICINES (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics

Ruilin Quan, Shian Huang, Lingpin Pang, Jieyan Shen, Weifeng Wu, Fangming Tang, Xiulong Zhu, Weiqing Su, Jingzhi Sun, Zaixin Yu, Lemin Wang, Xianyang Zhu, Changming Xiong, Jianguo He

Summary: This study aimed to explore outcome correlates and evaluate the incremental prognostic value of pulmonary hemodynamics for risk prediction in patients with pulmonary hypertension due to left heart disease (PH-LHD). The results showed that diastolic pressure gradient and mixed venous oxygen saturation were the most strongly associated hemodynamic predictors with mortality, and their inclusion in the risk prediction models improved the predictive ability.

BMC CARDIOVASCULAR DISORDERS (2022)

添加到收藏夹

Article Respiratory System

Ventilatory efficiency in pulmonary vascular diseases

Jason Weatherald, Brianne Philipenko, David Montani, Pierantonio Laveneziana

Summary: CPET is a common tool for differential diagnosis of dyspnoea, with ventilatory inefficiency being a hallmark characteristic of pulmonary vascular diseases. Understanding the mechanisms and diagnostic implications of ventilatory inefficiency is crucial in managing patients with these conditions.

EUROPEAN RESPIRATORY REVIEW (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Outcomes of atrial septostomy and effect on long-term survival in patients with idiopathic pulmonary arterial hypertension: A single-center cohort

Chaofan Xing, Xiaolei Wang, Xin Pan, Jie Yu, Cheng Wang, Yanjie Li, Linghong Shen, Ben He

Summary: This study retrospectively analyzed the effects and long-term survival rate of balloon atrial septostomy (BAS) in 12 patients with refractory right heart failure (RHF) from idiopathic pulmonary arterial hypertension (IPAH). The results showed that BAS improved hemodynamic variables and had clinical and cardiac functional benefits at 1-year follow-up. Although two patients died due to malignant arrhythmia and advanced heart failure, the overall survival rates at 1 and 3 years were 100% and 83.3% respectively.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Frataxin deficiency promotes endothelial senescence in pulmonary hypertension

Miranda K. Culley, Jingsi Zhao, Yi Yin Tai, Ying Tang, Dror Perk, Vinny Negi, Qiujun Yu, Chen-Shan C. Woodcock, Adam Handen, Gil Speyer, Seungchan Kim, Yen-Chun Lai, Taijyu Satoh, Annie M. M. Watson, Yassmin Al Aaraj, John Sembrat, Mauricio Rojas, Dmitry Goncharov, Elena A. Goncharova, Omar F. Khan, Daniel G. Anderson, James E. Dahlman, Aditi U. Gurkar, Robert Lafyatis, Ahmed U. Fayyaz, Margaret M. Redfield, Mark T. Gladwin, Marlene Rabinovitch, Mingxia Gu, Thomas Bertero, Stephen Y. Chan

Summary: The study reveals that endothelial cell senescence in pulmonary hypertension (PH) is associated with Fe-S deficiency, and Frataxin (FXN) protein may control endothelial cell senescence. FXN deficiency leads to senescence of vascular endothelial cells, promoting vascular inflammation and proliferative signals, driving disease progression.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Endothelial Senescence: A New Age in Pulmonary Hypertension

Miranda K. Culley, Stephen Y. Chan

Summary: This review discusses emerging concepts centered on endothelial senescence in pulmonary vascular disease. It proposes that endothelial senescence may serve as a unifying mechanism for pulmonary hypertension and highlights the link between aging and this disease. Additionally, it presents potential opportunities and barriers for targeting senescence in the diagnosis and treatment of pulmonary hypertension.

CIRCULATION RESEARCH (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Sleep apnea and pulmonary hypertension: A riddle waiting to be solved

Sunil Sharma, Robert Stansbury, Benjamin Hackett, Henrik Fox

Summary: Obstructive sleep apnea (OSA) and pulmonary hypertension (PH) are known to be associated, with limited understanding of the relationship which appears to be bidirectional. Limited data suggests that treatment with continuous positive pressure therapy may be beneficial and reduce pulmonary pressure. Further research on the mechanisms of this relationship is important.

PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Right Ventricular Sarcomere Contractile Depression and the Role of Thick Filament Activation in Human Heart Failure With Pulmonary Hypertension

Vivek Jani, M. Imran Aslam, Axel J. Fenwick, Weikang Ma, Henry Gong, Gregory Milburn, Devin Nissen, Ilton M. Cubero M. Salazar, Olivia Hanselman, Monica Mukherjee, Marc K. Halushka, Kenneth B. Margulies, Kenneth S. Campbell, Thomas C. Irving, David A. Kass, Steven Hsu

Summary: Right ventricular contractile dysfunction commonly occurs in patients with heart failure with reduced ejection fraction and pulmonary hypertension. Standard clinical indices may not reflect aspects of underlying myocyte dysfunction. This study investigates the mechanical properties of RV myocytes in HFrEF-PH patients and identifies potential underlying mechanisms.

CIRCULATION (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Myeloid Cell Derived IL1β Contributes to Pulmonary Hypertension in HFpEF

Vineet Agrawal, Jonathan A. Kropski, Jason J. Gokey, Elizabeth Kobeck, Matthew B. Murphy, Katherine T. Murray, Niki L. Fortune, Christy S. Moore, David F. Meoli, Ken Monahan, Yan Ru Su, Thomas Blackwell, Deepak K. Gupta, Megha H. Talati, Santhi Gladson, Erica J. Carrier, James D. West, Anna R. Hemnes

Summary: This study investigates whether a well-accepted murine model of HFpEF displays features of PH, and identifies potential pathways driving early remodeling of the pulmonary vasculature in HFpEF.

CIRCULATION RESEARCH (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Impact of bisoprolol and amlodipine on cardiopulmonary responses and symptoms during exercise in patients with chronic obstructive pulmonary disease

Chou-Chin Lan, Po-Chun Hsieh, I-Shiang Tzeng, Mei-Chen Yang, Chih-Wei Wu, Wen-Lin Su, Yao-Kuang Wu

Summary: Patients with COPD often experience exercise intolerance, and the prevalence of hypertension in these patients is high. β-blockers and amlodipine are commonly used antihypertensive drugs for COPD patients. This study aimed to investigate the effects of β-blockers and amlodipine on cardiopulmonary responses during exercise. The results showed that COPD patients taking β-blockers had lower blood oxygen concentration and increased leg fatigue during exercise, while patients taking amlodipine had lower respiratory rates during exercise. Other cardiopulmonary parameters were similar between patients with and without β-blockers or amlodipine.

PLOS ONE (2023)

添加到收藏夹

Review Medicine, General & Internal

Circulating Blood-Based Biomarkers in Pulmonary Hypertension

Marta Banaszkiewicz, Aleksandra Gasecka, Szymon Darocha, Michal Florczyk, Arkadiusz Pietrasik, Piotr Kedzierski, Michal Pilka, Adam Torbicki, Marcin Kurzyna

Summary: Pulmonary hypertension is a serious hemodynamic condition that can lead to right heart failure and death if not properly treated. The prognosis of pulmonary hypertension depends on various factors, and biomarkers provide information about disease severity, treatment response, and prognosis. However, due to the complexity of the condition, a single biomarker is not sufficient for evaluating different types of pulmonary hypertension patients.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-Term Survival

Javier Bermejo, Ana Gonzalez-Mansilla, Teresa Mombiela, Ana I. Fernandez, Pablo Martinez-Legazpi, Raquel Yotti, Rocio Garcia-Orta, Pedro L. Sanchez-Fernandez, Mario Castano, Javier Segovia-Cubero, Pilar Escribano-Subias, J. Alberto San Roman, Xavier Borras, Angel Alonso-Gomez, Javier Botas, Maria G. Crespo-Leiro, Sonia Velasco, Antoni Bayes-Genis, Amador Lopez, Roberto Munoz-Aguilera, Manuel Jimenez-Navarro, Jose R. Gonzalez-Juanatey, Arturo Evangelista, Jaime Elizaga, Javier Martin-Moreiras, Jose M. Gonzalez-Santos, Eduardo Moreno-Escobar, Francisco Fernandez-Aviles

Summary: The study reveals that the presence of pulmonary hypertension following successful correction of valvular heart disease is associated with a higher mortality rate, which is related to factors such as pulmonary vascular resistance, diabetes mellitus, and residual effective valve area. These findings have significant implications for individualizing valve correction procedures.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The Value of Passive Leg Raise During Right Heart Catheterization in Diagnosing Heart Failure With Preserved Ejection Fraction

Arno A. van de Bovenkamp, Niels Wijkstra, Frank P. T. Oosterveer, Anton Vonk Noordegraaf, Harm Jan Bogaard, Albert C. van Rossum, Frances S. de Man, Barry A. Borlaug, M. Louis Handoko

Summary: PCWPPLR during a passive leg raise can be a simple and powerful tool to diagnose or rule out occult-HFpEF, especially for patients with normal left ventricular filling pressures at rest.

CIRCULATION-HEART FAILURE (2022)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Heart failure with normal natriuretic peptide levels: more fat, and that is the main problem

Frederik H. Verbrugge, Barry A. Borlaug

EUROPEAN HEART JOURNAL (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets

Barry A. Borlaug, Michael D. Jensen, Dalane W. Kitzman, Carolyn S. P. Lam, Masaru Obokata, Oliver J. Rider

Summary: Obesity and heart failure with preserved ejection fraction (HFpEF) are two intertwining epidemics, and obesity may have widespread effects on the cardiovascular system, leading to symptomatic HFpEF. Understanding the pathophysiological mechanisms of obese HFpEF is crucial for developing new therapeutic approaches.

CARDIOVASCULAR RESEARCH (2023)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Longitudinal Evolution of Cardiac Dysfunction in Heart Failure and Preserved Ejection Fraction With Normal Natriuretic Peptide Levels

Hidemi Sorimachi, Frederik H. Verbrugge, Kazunori Omote, Massar Omar, Masaru Obokata, Yogesh N. V. Reddy, Zi Ye, Hector I. Michelena, Barry A. Borlaug

CIRCULATION (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions

Anthony E. Peters, Jasper Tromp, Sanjiv J. Shah, Carolyn S. P. Lam, Gregory D. Lewis, Barry A. Borlaug, Kavita Sharma, Ambarish Pandey, Nancy K. Sweitzer, Dalane W. Kitzman, Robert J. Mentz

CARDIOVASCULAR RESEARCH (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Improvement in Renal Function During the Treatment of Acute Decompensated Heart Failure: Relationship With Markers of Renal Tubular Injury and Prognostic Importance

Peter S. Natov, Juan B. Ivey-Miranda, Zachary L. Cox, Julieta Moreno-Villagomez, Christopher Maulion, Lavanya Bellumkonda, Michael G. Shlipak, Michelle M. Estrella, Barry A. Borlaug, Veena S. Rao, Jeffrey M. Testani

Summary: Improvement in renal function in acute decompensated heart failure is associated with adverse outcomes, and the mechanisms behind this paradox remain unclear. In this study, patients were classified into improvement, worsening, and stable renal function groups, and renal tubular injury markers were evaluated. The results showed that patients with improvement in renal function had the lowest admission estimated glomerular filtration rate, but had greater urine output and weight loss compared to the stable renal function group. However, improvement in renal function was not associated with improved markers of renal tubular injury and was associated with worse survival.

CIRCULATION-HEART FAILURE (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials

Michael E. Nassif, Sheryl L. Windsor, Kensey Gosch, Barry A. Borlaug, Mansoor Husain, Silvio E. Inzucchi, Dalane W. Kitzman, Darren K. McGuire, Bertram Pitt, Benjamin M. Scirica, Sanjiv J. Shah, Guillermo Umpierrez, Bethany A. Austin, Sumant Lamba, Taiyeb Khumri, Kavita Sharma, Mikhail N. Kosiborod

Summary: The benefits of SGLT2 inhibitors on symptoms and physical limitations in patients with heart failure are consistent and clinically meaningful across the full range of ejection fraction (EF), according to a pooled analysis of two trials.

CIRCULATION-HEART FAILURE (2023)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

SGLT2 inhibitors and diuretics in heart failure: clicking reset on the renal volume setpoint?

Barry A. Borlaug, Jeffrey M. Testani

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Letter Peripheral Vascular Disease

Daytime Versus Nighttime Ambulatory Blood Pressure Monitoring in Coarctation of Aorta

Alexander C. Egbe, William R. Miranda, Heidi M. Connolly, Iftikhar J. Kullo, Barry A. Borlaug

HYPERTENSION (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial

Barry A. Borlaug, Yogesh N. V. Reddy, Amanda Braun, Hidemi Sorimachi, Massar Omar, Dejana Popovic, Alessio Alogna, Michael D. Jensen, Rickey Carter

Summary: This study found that treatment with dapagliflozin can reduce pulmonary capillary wedge pressure (PCWP) at rest and during exercise in patients with HFpEF, and has favorable effects on plasma volume and body weight.

CIRCULATION (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prevalence and incidence of diastolic dysfunction in atrial fibrillation: clinical implications

Jwan A. Naser, Eunjung Lee, Christopher G. Scott, Austin M. Kennedy, Patricia A. Pellikka, Grace Lin, Sorin Pislaru, Barry A. Borlaug

Summary: This study aimed to investigate the prevalence and incidence of DD in patients with new-onset AF compared with SR. The results showed that patients with new-onset AF have high-risk features for HFpEF at diagnosis and accelerated progression in DD over time.

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Surgical pericardiotomy to treat heart failure with preserved ejection fraction: a first clinical study

Barry A. Borlaug, Hartzell Schaff, Samuel J. Asirvatham, Katlyn E. Koepp, William J. Mauermann, Phillip G. Rowse

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Article Medicine, General & Internal

Obesity, Cardiorenal Comorbidities, and Risk of Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction

Camilla S. Morgen, Christiane L. Haase, Tugce K. Oral, Volker Schnecke, Anette Varbo, Barry A. Borlaug

Summary: This study compares clinical features of patients with obesity-related HFpEF with those of non-HF patients matched on BMI, and examines the association between degree of obesity and risk for hospitalizations. The results show that HFpEF patients have worse kidney function, greater plasma volume, and more cardiovascular comorbidities compared to the control group. Among HFpEF patients, those with higher degree of obesity are younger, have fewer cardiovascular comorbidities, and have an increased risk of HF-related hospitalizations.

MAYO CLINIC PROCEEDINGS (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Barry A. Borlaug, Dalane W. Kitzman, Melanie J. Davies, Soren Rasmussen, Eric Barros, Javed Butler, Mette Nygaard Einfeldt, G. Kees Hovingh, Daniel Vega Moller, Mark C. Petrie, Sanjiv J. Shah, Subodh Verma, Walter Abhayaratna, Fozia Z. Ahmed, Vijay Chopra, Justin Ezekowitz, Michael Fu, Hiroshi Ito, Malgorzata Lelonek, Vojtech Melenovsky, Julio Nunez, Eduardo Perna, Morten Schou, Michele Senni, Peter van der Meer, Dirk Von Lewinski, Dennis Wolf, Mikhail N. Kosiborod

Summary: In the STEP-HFpEF trial, semaglutide demonstrated positive treatment effects on symptoms, physical limitations, exercise function, and body weight in patients with the obesity phenotype of heart failure with preserved ejection fraction (HFpEF). The results showed that semaglutide consistently improved outcomes across different obesity categories and the magnitude of benefit was directly related to the extent of weight loss.

NATURE MEDICINE (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cardiac dysfunction rather than aortic valve stenosis severity drives exercise intolerance and adverse haemodynamics

Sarah Hoedemakers, Jan Verwerft, Yogesh N. Reddy, Robin Delvaux, Sarah Stroobants, Siddharth Jogani, Guido Claessen, Steven Droogmans, Bernard Cosyns, Barry A. Borlaug, Lieven Herbots, Frederik H. Verbrugge

Summary: The study aimed to examine the impact of HFpEF vs. AS lesion severity on various cardiac parameters and exercise capacity. The results showed that a high H2FPEF score was associated with reduced exercise capacity and adverse hemodynamics in patients with moderate to severe AS.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.